EP Patent

EP2119783A1 — Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means

Assigned to Prosensa Technologies BV · Expires 2009-11-18 · 16y expired

What this patent protects

The invention provides a method for modulating skipping of Duchenne Muscular Dystrophy (DMD) gene in a cell. More specifically, the invention provides methods and means for modulating skipping of exon 44 of DMD. The invention further provides nucleic acid molecules that can be us…

USPTO Abstract

The invention provides a method for modulating skipping of Duchenne Muscular Dystrophy (DMD) gene in a cell. More specifically, the invention provides methods and means for modulating skipping of exon 44 of DMD. The invention further provides nucleic acid molecules that can be used for a method of the invention, expression methods for expression of a nucleic acid molecule in a cell, and use of a nucleic acid molecule for modulating skipping of DMD in a cell.

Drugs covered by this patent

Patent Metadata

Patent number
EP2119783A1
Jurisdiction
EP
Classification
—
Expires
2009-11-18
Drug substance claim
No
Drug product claim
No
Assignee
Prosensa Technologies BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.